Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Anti-coagulation therapy Clear all
Completed Not applicable Interventional Results available

Randomized On-X Anticoagulation Trial

NCT00291525
View directory record Official record
Conditions
Heart Valve Disease
Interventions
On-X valve using reduced anticoagulation, On-X Valve with Standard warfarin Therapy
Device
Lead sponsor
On-X Life Technologies, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
44
States / cities
Tucson, Arizona • Loma Linda, California • Hartford, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:03 AM EDT
Recruiting Phase 3 Interventional

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

NCT04563520
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, FEIBA, rFVIIa
Drug
Lead sponsor
Emory University
Other
Eligibility
6 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 8:03 AM EDT
Terminated Phase 1 Interventional

Comparison Between Point of Care Device and Venous Blood International Normalized Ratio Measurements.

NCT00288808
View directory record Official record
Conditions
Blood Coagulation Disorder
Interventions
Hemosense (PT/InR point of care device)
Device
Lead sponsor
University of Rochester
Other
Eligibility
1 Day to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

NCT01954238
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GCC-4401C, Rivaroxaban, Placebo
Drug
Lead sponsor
Green Cross Corporation
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Early Phase Clinical Unit _Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 19, 2026, 8:03 AM EDT
Not listed Not applicable Interventional

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)

NCT01213914
View directory record Official record
Conditions
Burns, Hemofiltration, Kidney Failure, Acute, Shock, Septic
Interventions
An FDA approved continuous renal replacement device, Control Group
Device · Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF

NCT03583008
View directory record Official record
Conditions
Atrial Fibrillation, Prescribing Practices, Anticoagulants
Interventions
Anticoagulation (AC) Intervention--Academic Detailing, Anticoagulation (AC) Intervention--Prescribing Practices
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

NCT00525447
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SGN-40, lenalidomide, dexamethasone
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Denver, Colorado • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 19, 2026, 8:03 AM EDT
Completed No phase listed Observational

Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

NCT01477528
View directory record Official record
Conditions
Anticoagulation, Left Ventricular Assist Device
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
San Diego, California • Gainesville, Florida • Oak Lawn, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2022 · Synced Oct 19, 2026, 8:03 AM EDT
Recruiting Not applicable Interventional

Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation

NCT05723926
View directory record Official record
Conditions
Atrial Fibrillation, Oral Anticoagulation, Stroke, Implant
Interventions
Vine Filter
Device
Lead sponsor
Javelin Medical
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Rockford, Illinois • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

NCT03061006
View directory record Official record
Conditions
Dementia, Cognition Disorders, Cerebral Ischemic Events
Interventions
Dabigatran Etexilate, Warfarin
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
65 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 19, 2026, 8:03 AM EDT
Recruiting Phase 3 Interventional

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713
View directory record Official record
Conditions
Community-acquired Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 8:03 AM EDT
Terminated No phase listed Observational

Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode

NCT02019030
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Loma Linda, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Not applicable Interventional

The Effect of Patellar Eversion on Functional Outcomes in Primary Total Knee Arthroplasty

NCT01777009
View directory record Official record
Conditions
Total Knee Replacement, Arthroplasty, Patella
Interventions
Primary Total Knee Replacement Surgery
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

NCT04409834
View directory record Official record
Conditions
COVID-19, Venous Thromboembolism, Arterial Thrombosis
Interventions
Unfractionated Heparin IV, Enoxaparin 1 mg/kg, Clopidogrel, Unfractionated heparin SC, Enoxaparin 40 mg SC
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 19, 2026, 8:03 AM EDT
Recruiting Phase 4 Interventional

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332
View directory record Official record
Conditions
Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions
Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care
Other · Diagnostic Test
Lead sponsor
Region Skane
Other
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation

NCT01294267
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Circulatory Support System
Device
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 19, 2026, 8:03 AM EDT
Completed No phase listed Observational

Study of Procoagulation Markers in Stroke Patients

NCT01811550
View directory record Official record
Conditions
Stroke, Hyperglycemia, Procoagulation Markers
Interventions
Glycemic Control
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 19, 2026, 8:03 AM EDT
Recruiting Not applicable Interventional

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
48
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

NCT00401414
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation
Interventions
Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 19, 2026, 8:03 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 19, 2026, 8:03 AM EDT
Completed Not applicable Interventional

Genotype-Guided Warfarin Therapy Trial

NCT00904293
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
Interventions
Genotype-guided dose determination, Non-genotype guided warfarin dosing
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 19, 2026, 8:03 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

NCT04077463
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 19, 2026, 8:03 AM EDT